Related Experiment Video
Updated: May 28, 2026

Photodynamic Therapy with Blended Conducting Polymer/Fullerene Nanoparticle Photosensitizers
Published on: October 28, 2015
An Anthracenyl-Functionalized Boron Dipyrromethene Based Glutathione-Responsive Nanoplatform for Efficient
Xingcan Li1, Lixia Bai1, Yicheng Wang1
1Key Laboratory of Catalysis and Energy Materials Chemistry of Ministry of Education & Hubei Key Laboratory of Catalysis and Materials Science & Key Laboratory of Analytical Chemistry of the State Ethnic Affairs Commission, School of Chemistry and Materials Science, South-Central Minzu University, Wuhan, China.
Abstract:
Photodynamic therapy (PDT) relies on light-activated photosensitizers to generate cytotoxic reactive oxygen species (ROS) for cancer treatment. However, its efficacy is severely limited by tumor microenvironment (TME) features such as hypoxia and elevated antioxidant levels (e.g., glutathione, GSH). To address these challenges, a GSH-responsive nanoplatform (enBDP-F NPs) was developed by integrating a heavy-atom-free photosensitizer (enBDP) with perfluorooctanoic acid (PFOA). The donor-acceptor-structured enBDP, featuring an anthracene-modified BODIPY core, enables efficient ROS generation via a spin-orbit charge transfer intersystem crossing (SOCT-ISC) mechanism. In the TME, enBDP-F NPs undergo GSH-triggered disassembly, releasing PFOA to alleviate hypoxia while simultaneously depleting intracellular GSH through disulfide bond cleavage, thereby disrupting redox homeostasis and suppressing ROS scavenging. This dual-responsive mechanism synergistically enhances oxidative stress and promotes tumor cell death. Both in vitro and in vivo studies demonstrate that enBDP-F NPs exhibit minimal dark toxicity but potent phototoxicity, significantly suppress tumor growth, reduce 4T1 cell viability to below 20% under irradiation, and display an oxygen-carrying capacity approximately threefold higher than PBS. This work provides a promising strategy for synergistic TME modulation to enhance PDT efficacy in cancer therapy.

